Phigenix Seeks Strategic Collaboration for New Technology Development

Written By Carlton Donald

Based on exciting new data involving detecting and targeting the PAX2 oncogene for cancer treatment, Phigenix is seeking partnerships to advance current programs, and for the development of new products encompassing our unique cancer target and companion diagnostics for personalized medicine.

Carlton Donald
Previous

USPTO Director Andrei Iancu Lauds Risk Takers, Calls Patent Troll Narrative ‘Orwellian doublespeak’
Next

PTAB Invalidates Patent Covering Breast Cancer Treatment